Search results for "retrospective studie"

showing 10 items of 3102 documents

Repeated kidney re-transplantation—the Eurotransplant experience: a retrospective multicenter outcome analysis

2020

Transplant international (2020). doi:10.1111/tri.13569

re-transplantationOutcome analysis030230 surgeryKidneyALLOCATION0302 clinical medicine3RDfourthKidney transplantationKidneychildGraft SurvivalConfoundinglossSUCCESSrepeatedGRAFT LOSSCOMPETING RISKSTissue Donorsddc:Treatment Outcomesurgical procedures operativemedicine.anatomical_structure030211 gastroenterology & hepatologyOutcome dataLife Sciences & Biomedicinemedicine.medical_specialtykidneyTissue and Organ ProcurementRe transplantation610survival1ST03 medical and health sciencesmedicineHumansddc:6102NDRetrospective StudiesDeceased donorTransplantationScience & Technologybusiness.industrymedicine.diseaseKidney TransplantationSurgeryTransplantationRECIPIENTSgraftSurgeryHuman medicinebusinessthirdSINGLE-CENTER
researchProduct

Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection

2022

Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-alpha therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion to positive TBC status among patients with psoriasis treated with second-generation biologic therapies, particularly anti-interleukin (IL)-17 therapies such as secukinumab. Objectives To evaluate the safety profile of secukinumab in psoriasis patients with latent TBC infection. Methods Real-life data were collected by retrospective chart review on patients with moderate-to-severe psoriasis who showed positivity for TBC screening at baseline an…

reactivationBiologicpsoriasis.latent tuberculosis infectionsecukinumabchemoprophylaxisDermatologyBiologicsBiologics; chemoprophylaxis; latent tuberculosis infection; psoriasis; reactivation; secukinumab.Antibodies Monoclonal HumanizedSeverity of Illness IndexTreatment OutcomeLatent TuberculosisIsoniazidHumansPsoriasisTuberculosisRifampinchemoprophylaxiRetrospective Studiespsoriasi
researchProduct

Clinical assessment and comparison of ACL reconstruction using synthetic graft (Neoligaments versus FiberTape).

2021

Background Due to the low potential for primary biological healing of the anterior cruciate ligament (ACL), the most popular approach is currently reconstruction using a graft. Recent research indicates that the technique of strengthening a damaged ligament with synthetic tapes (internal bracing) may be an alternative to reconstructive treatment, especially in cases of partial ACL damage. Objectives To compare and evaluate the possibility of using a synthetic graft (Neoligaments or FiberTape) to treat partial lesions of the ACL. Material and methods This was a retrospective cohort study. Selected from a pool of 128 patients undergoing primary unilateral intra-articular ACL reconstruction du…

reconstructionKnee JointAnterior cruciate ligamentMedicine (miscellaneous)primary repairGroup comparisonKnee JointLachman testGeneral Biochemistry Genetics and Molecular BiologyInternal MedicinemedicineHumansPharmacology (medical)internal bracingAnterior Cruciate LigamentGenetics (clinical)Retrospective StudiesOrthodonticsAnterior Cruciate Ligament Reconstructionbusiness.industryAnterior Cruciate Ligament InjuriesRetrospective cohort studySynthetic graftmusculoskeletal systemathletesmedicine.anatomical_structureTreatment OutcomeReviews and References (medical)LigamentbusinessRange of motionhuman activitiesAdvances in clinical and experimental medicine : official organ Wroclaw Medical University
researchProduct

Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers: The GI…

2007

OBJECTIVE: To assess the prevalence of good clinical response and remission in rheumatoid arthritis (RA) patients with longstanding disease treated with anti-tumor necrosis factor-alpha (TNF-alpha) drugs at outpatient clinics. METHODS: Retrospective national study of 14 academic tertiary referral rheumatology medical centers. RA patients with a Disease Activity Score (DAS28) > 3.2 were defined as having active disease and could start TNF-alpha blockers. All patients received one TNF-alpha blocker plus methotrexate (10-20 mg/wk). At the third month the patients were categorized as responders or nonresponders, based on improvement of at least 0.25 of the Health Assessment Questionnaire (HAQ).…

rheumatoid arthritisAdultMaleQuality Assurance Health Carepredictors of remissionTumor Necrosis Factor blockersAntibodies Monoclonal HumanizedSeverity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptArthritis RheumatoidRheumatoid arthritis; Good clinical response; Tumor Necrosis Factor blockersPredictive Value of TestsHumansRheumatoid arthritispredictors of remission; rheumatoid arthritis; tumor necrosis factor-alpha blockersAgedRetrospective StudiesGood clinical responseTumor Necrosis Factor-alphatumor necrosis factor-alpha blockersRemission InductionAdalimumabAntibodies MonoclonalMiddle AgedPrognosisInfliximabLogistic ModelsMethotrexateTreatment Outcomedisability score; good clinical response; remission; rheumatoid arthritis; tumor necrosis factor-α blockersItalyAntirheumatic AgentsImmunoglobulin GFemale
researchProduct

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side ef…

2007

Objective: To evaluate the efficacy of switching to etanercept treatment in patients with rheumatoid arthritis who already responded to infliximab, but presented side effects. Methods: Charts of 553 patients with rheumatoid arthritis were retrospectively reviewed to select patients who responded to the treatment with infliximab and switched to etanercept because of occurrence of adverse effects. Clinical data were gathered during 24 weeks of etanercept treatment and for the same period of infliximab treatment before infliximab was stopped. Disease Activity Score computed on 44 joints (DAS-44), erythrocyte sedimentation rate (ESR) 1st hour, Visual Analogue Scale (VAS) of pain, Health Assessm…

rheumatoid arthritisMaleConcise ReportArthritisGastroenterologyReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis Rheumatoidimmune system diseasesImmunology and AllergyHealth Status Indicatorsskin and connective tissue diseasesmedicine.diagnostic_testbiologyAntibodies MonoclonalMiddle AgedC-Reactive ProteinTreatment OutcomeBiologic agents; etanercept; infliximab; infusion reactionRheumatoid arthritisErythrocyte sedimentation rateAntirheumatic AgentsFemalemedicine.drugmusculoskeletal diseasesAdultmedicine.medical_specialtyVisual analogue scaleImmunologyBlood Sedimentationinfusion reactionGeneral Biochemistry Genetics and Molecular BiologyRheumatologyInternal medicinemedicineHumansAdverse effectRetrospective StudiesChi-Square Distributionbusiness.industryTumor Necrosis Factor-alphaC-reactive proteinetanercept; infliximab; rheumatoid arthritismedicine.diseaseInfliximabInfliximabSurgeryBiologic agentsstomatognathic diseasesImmunoglobulin Gbiology.proteinbusinessinfliximabetanercept
researchProduct

Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma

2021

BACKGROUND: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. METHODS: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow-up. The primary outcome was the evolution of…

severe asthmamedicine.medical_specialtyPediatricsImmunology*real lifeOmalizumabhumanized monoclonal antibodiesOmalizumab*adolescentsAntibodies Monoclonal HumanizedAnti-asthmatic Agent03 medical and health sciences0302 clinical medicinechildrenreal lifeInternal medicinemedicine*anti-asthmatic agents*childrenHumansImmunology and AllergyChildren adolescents anti-asthmatic agents humanized monoclonal antibodies observational study omalizumab real-life severe asthmaAnti-Asthmatic Agentsadolescents030212 general & internal medicineChildAdverse effectRetrospective Studiesbusiness.industryasthmatic agents*observational studyanti&#8208Retrospective cohort studyAsthmaDiscontinuation*omalizumabTreatment OutcomePulmonology030228 respiratory system*humanized monoclonal antibodies*severe asthmaSevere persistent allergic asthmaPediatrics Perinatology and Child HealthCohortomalizumabobservational studyObservational studybusinessmedicine.drugPediatric Allergy and Immunology
researchProduct

Prognostic value of HSP27 in head and neck squamous cell carcinoma: a retrospective analysis of 57 tumours.

2006

Background: The aims of the present study were to assess the prevalence of HSP27 expression in oral squamous cell carcinoma (OSCC) and to verify whether HSP27 can be considered to be a marker of prognosis in patients with OSCC. Materials and Methods: The immunohistochemical expression of HSP27 was evaluated in 57 OSCC, who received standard treatment and monitoring. After grouping for HSP27 expression, OSCCs were statistically analysed for the variables age, gender, histological grading, TNM, staging and survival rate. Univariate and multivariate analyses were performed. Results: HSP27 was found to be reduced in 31 OSCC and was normally expressed in 26 OSCC. The pattern and intensity of HSP…

squamous cell carcinomaAdultAged 80 and overMaleAdolescentHSP27Middle AgedPrognosissurvivalImmunohistochemistrySurvival RateLogistic ModelsHead and Neck NeoplasmsCarcinoma Squamous CellHumanshead and neck cancerFemaleHeat-Shock ProteinsAgedNeoplasm StagingRetrospective StudiesAnticancer research
researchProduct

Oral pigmented lesions:a retrospective analysis from Brazil

2020

Background Pigmented lesions are uncommon in the oral mucosa, and studies investigating the incidence and types of these lesions are desired to improve the diagnostic knowledge of clinicians. The aim of this study was to analyze the distribution of oral pigmented lesions in a Brazilian population. Material and Methods A retrospective descriptive cross-sectional study was performed. Oral pigmented lesions were retrieved from the files of two oral and maxillofacial pathology services from Brazil over a 45-year period (1974-2019). The clinical data and the diagnoses of each case were retrieved and included in a Microsoft Excel® database. Results From 77.074 lesions diagnosed in this period, 76…

squamous cell carcinomamedicine.medical_specialtymalignant transformationLesionDiagnosis Differentialpotentially malignant disordersOral and maxillofacial pathologymedicineNevusHumansOral mucosaGeneral DentistryUNESCO:CIENCIAS MÉDICASRetrospective StudiesOral Medicine and Pathologybusiness.industryMelanotic neuroectodermal tumor of infancyResearchAmalgam tattooMouth Mucosamedicine.diseaseDermatologyMelanoacanthomaMelanosismedicine.anatomical_structureCross-Sectional StudiesOtorhinolaryngologyleukoplakiaSurgeryFemalemedicine.symptombusinessMouth DiseasesBrazil
researchProduct

Peri-Implant Behavior of Tissue Level Dental Implants with a Convergent Neck

2021

Introduction: The aim of this retrospective study was to analyze the radiographic peri-implant bone loss of bone level implants and tissue level implants with a convergent neck in screw-retained single crowns and in screw-retained fixed partial prostheses, after two years of functional loading. Materials and methods: The sample was divided into two groups according to their type: Group I: supracrestal implants with convergent transmucosal neck

tissue levelHealth Toxicology and MutagenesisRadiographymedicine.medical_treatmentPeriAlveolar Bone LossDentistryMandibleProsthesisArticleBones.Dental implants.03 medical and health sciences0302 clinical medicinebone lossMaxillamedicineHumansHuesos.Dental Restoration FailureOdontología restauradora.Bone levelRetrospective StudiesDental Implantsbusiness.industryfixed partial prosthesisPrótesis dentales.Dientes - Implantes.RPublic Health Environmental and Occupational HealthMandibleTissue levelbone level030206 dentistryDentures.Treatment Outcomesingle crownMaxillaMedicineImplantbusinessDentistry Operative.Follow-Up Studies030215 immunologyInternational Journal of Environmental Research and Public Health
researchProduct

Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy

2015

Recently, many studies explored the role of inflammation parameters in the prognosis of urinary cancers, but the results were not consistent. The modified Glasgow Prognostic Score (mGPS), a systemic inflammation marker, is a prognostic marker in various types of cancers. The aim of the present study was to investigate the usefulness of the preoperative mGPS as predictor of recurrence-free (RFS), overall (OS), and cancer-specific (CSS) survivals in a large cohort of urothelial bladder cancer (UBC) patients.A total of 1037 patients with UBC were included in this study with a median follow-up of 22 months (range 3-60 months). An mGPS = 0 was observed in 646 patients (62.3%), mGPS = 1 in 297 pa…

to-lymphocyte ratioAdultMaleRiskmedicine.medical_specialtyPrognosimedicine.medical_treatmentCystectomyGastroenterologySettore MED/24 - UrologiaCystectomyMedicine (all); c-reactive protein; advanced urothelial carcinoma; to-lymphocyte ratioc-reactive proteinRetrospective StudieInternal medicine80 and overHumansMedicineStage (cooking)advanced urothelial carcinomaRetrospective StudiesAgedAged 80 and overModified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience.Univariate analysisBladder cancerbusiness.industryProportional hazards modelMedicine (all)Hazard ratioBladder cancer Radical cystectomyRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurgeryNeoplasm RecurrenceLocalUrinary Bladder NeoplasmsUrinary Bladder NeoplasmCohortFemaleNeoplasm Recurrence LocalAdult; Aged; Aged 80 and over; Female; Humans; Male; Middle Aged; Neoplasm Recurrence Local; Prognosis; Retrospective Studies; Risk; Urinary Bladder Neoplasms; Cystectomy; Medicine (all)businessHumanMedicine
researchProduct